Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer

NCT04179864 is registered in ClinicalTrials.gov with Epizyme, Inc. as lead sponsor.

NCT NCT04179864
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04179864 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
Epizyme, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
November 18, 2019
Completion date
November 4, 2024
Enrollment
102 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer, metastatic prostate cancer